Centre for Psychedelic Research, Division of Psychiatry, Department of Brain Sciences, Imperial College London, London, UK.
Unit for Pharmacokinetics and Drug Metabolism, Department of Pharmacology, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden.
J Psychopharmacol. 2024 Jan;38(1):56-67. doi: 10.1177/02698811231196877. Epub 2023 Oct 28.
N,N-Dimethyltryptamine (DMT) is a serotonergic psychedelic that induces a rapid and transient altered state of consciousness when inhaled or injected via bolus administration. Its marked and novel subjective effects make DMT a powerful tool for the neuroscientific study of consciousness and preliminary results show its potential role in treating mental health conditions. In a within-subjects, placebo-controlled study, we investigated a novel method of DMT administration involving a bolus injection paired with a constant-rate infusion, with the goal of extending the DMT experience. Pharmacokinetic parameters of DMT estimated from plasma data of a previous study of bolus intravenous DMT were used to derive dose regimens necessary to keep subjects in steady levels of immersion into the DMT experience over an extended period of 30 min, and four dose regimens consisting of a bolus loading dose and a slow-rate infusion were tested in eleven healthy volunteers (seven male, four female, mean age ± SD = 37.09 ± 8.93 years). The present method is effective for extending the DMT experience in a stable and tolerable fashion. While subjective effects were maintained over the period of active infusion, anxiety ratings remained low and heart rate habituated within 15 min, indicating psychological and physiological safety of extended DMT. Plasma DMT concentrations increased consistently starting 10 min into DMT administration, whereas psychological effects plateaued into the desired steady state, suggesting the development of acute psychological tolerance to DMT. Taken together, these findings demonstrate the safety and effectiveness of continuous IV DMT administration, laying the groundwork for the further development of this method of administration for basic and clinical research.
N,N-二甲基色胺(DMT)是一种血清素能致幻剂,吸入或通过推注给药静脉注射时会迅速短暂地改变意识状态。其明显而新颖的主观效应使 DMT 成为研究意识的神经科学的有力工具,初步结果显示其在治疗心理健康状况方面的潜力。在一项个体内、安慰剂对照研究中,我们研究了一种新的 DMT 给药方法,涉及推注给药与恒速输注相结合,目的是延长 DMT 体验。从以前静脉内 DMT 推注研究的血浆数据中估计的 DMT 药代动力学参数用于推导出在 30 分钟的延长时间内使受试者保持稳定沉浸在 DMT 体验中的剂量方案,并且在 11 名健康志愿者(7 名男性,4 名女性,平均年龄±SD=37.09±8.93 岁)中测试了四种剂量方案,包括推注负荷剂量和慢输注。目前的方法可有效稳定且可耐受地延长 DMT 体验。虽然在主动输注期间保持了主观效应,但焦虑评分仍然较低,心率在 15 分钟内适应,表明延长 DMT 的心理和生理安全性。在开始 DMT 给药后 10 分钟,血浆 DMT 浓度持续升高,而心理效应达到所需的稳态,表明 DMT 急性心理耐受性的发展。总之,这些发现证明了连续 IV DMT 给药的安全性和有效性,为进一步开发这种给药方法进行基础和临床研究奠定了基础。